Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 8 December 2020 to Question 122697 on Coronavirus: Vaccination, how much funding his Department plans to allocate towards vaccine research that does not involve human fetal tissue in its development, production and laboratory testing in 2021; and whether his Department has plans to increase the level of such funding in future years.

The Department’s Research and Development (R&D) settlement has increased to £11.1 billion for 2021/22. This settlement supports our commitments as set out in the R&D Roadmap and helps to consolidate our position as a science superpower. Specific funding is subject to our departmental allocations process, which is now underway and progressing at pace, including the allocation of this funding to UK Research and Innovation (UKRI).

Most of the research into vaccines for human use that is funded by the Department is carried out through the Medical Research Council (MRC), part of UKRI. The latest available data shows that in 2017/18, the MRC funded £25 million into research aimed at developing vaccines. This data does not record whether this work involved the use of aborted human foetal tissue.

Any use of such tissue would require an ethical review and must be in accordance with legal requirements. The MRC has produced guidance on the ethical and legal requirements for the use of human tissue in the research that it funds.

UKRI welcomes high quality applications for support into any aspect of human health and these are judged in open competition with other demands on funding. Awards are made according to their scientific quality and importance to human health. Where specific funding is allocated in advance for a strategic area of research, such as vaccines, such allocations would not normally specify the research methodology to be used.